Amarin Message Board

also wondering any updates??

“As a company focused for more than a decade on fighting cardiovascular disease, which in the United States alone results in one stroke, heart attack or death every 14 seconds, we are determined to do our part to protect public health and the health of our many valued employees,” said John Thero, president and chief executive officer of Amarin. “We have developed a roadmap of remote working activities for us to continue to help many patients with persistent cardiovascular risk, including u…

and a run to $29 is possible with a favorable ruling.

AMRN would def start the process of reviving GILD's cardiovascular business.

Are those week-to-week numbers considered good growth at this stage of the game with the new label?

Amarin has done a great job increasing their patents...

I've read conflicting reports with some saying an Amarin victory in the patent trial is a sure thing and then there are those saying it isn't and there is a real possibility we lose the case. What happens if Amarin loses? Will there be major layoffs, stock cut in half, and revenue projections cut in half as well?

"Our Time, Their Future" followed with a mic drop. Then he left for San Francisco.

JT elaborated on this in the breakout at JPM -

On salesforce expansion: "I think there's still some question if 800 is the ideal number or not. It may be larger than that," Thero says. Adds it's possible for incremental expansion in 2020 if sales reps pay for themselves. H/T BioPharmaDive

Thero even talked about not wanting to get a European partner yet, calling it pre-mature, which is interesting.

What's more likely to happen with Amarin at the JP Morgan Healthcare Conference?

A. Amarin's patent infringement case settles during the week of the meeting

B. Amarin gets acquired for > $20 billion

C. JT skips his presentation to hang out with the sea lions at Fisherman's Wharf

D. All of the above

Feuerstein's twitter game is heavily focused on Amarin for some reason.

Here is the Matinas CEO in an interview post Vascepa label expansion, saying everything that JT meant to say on CNBC but couldn't articulate properly.